Ideaya Biosciences (IDYA) provided updated guidance related to the timing of its upcoming topline data release from the Phase 2/3 OptimUM-02 trial in first-line HLA-A2-negative metastatic uveal melanoma. The database lock is projected in the first half of April, followed by the topline data analysis thereafter. A live investor and analyst webcast will be hosted by Ideaya management and a guest key opinion leader, the company said.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences falls -6.0%
- IDEAYA Biosciences: Operational Trial Delay but High Conviction Buy Ahead of Key Darovasertib Readout
- IDEAYA Biosciences: Expanding Precision Oncology Platform and Refocused MTAP Strategy Support Buy Rating
- Ideaya Biosciences enrolls first patient in IDE892 trial
- Citi opens ‘upside 90-day catalyst watch’ on Ideaya Biosciences